Suraksha Diagnostic IPO GMP grey market premium, review, Subscription, allotment, listing estimate @ Chanakyanipothi.com
A legacy of 31 Years.
India`s Oldest Investment & IPO website.
Most Trusted by Investors across India.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
What is the latest news relating to Suraksha Diagnostic IPO?
On 6th December 2024, the scrip is listed at RS. 438, discount of 0.68% over the issue price.
Suraksha Diagnostic IPO Subscription Status
Suraksha Diagnostic IPO Subscriptions
|
|||||
| QIB | B HNI X | S HNI X | NII X | RII X | Total X |
| 1.74 | 1.53 | 1.16 | 1.40 | 0.94 | 1.27 |
| Applications: 1,47,938 / (147.94x) Amount wise Bids recd. Rs. ? Crore |
|||||
Suraksha Diagnostic IPO Allotment Link:
We will provide allotment link, once the allotment is finalised.
Who are the promoter of Suraksha Diagnostic IPO?
The promoters of the company are Dr. Somnath Chatterjee, Ritu Mittal and Satish Kumar Verma.
What are the Objects of Suraksha Diagnostic IPO?
The Offer comprises only of an Offer for Sale by the Selling Shareholders and all proceeds will go to the Selling Shareholders.
A Note on the business of Suraksha Diagnostic?
Suraksha Diagnostics the largest full-service and integrated diagnostic chain headquartered in east India, by operating income as of Fiscal 2023. It also reported the highest compounded annual growth rate (“CAGR”) of 20.87% in terms of non-COVID revenues between Fiscals 2022 and 2024 among peers Agilus Diagnostics Limited, Dr. Lal Pathlabs Limited, Metropolis Healthcare Limited, Thyrocare Technologies Limited.
Founded on March 15, 2005, Suraksha Diagnostic Limited is a technology-driven diagnostic chain providing integrated solutions in pathology, radiology, and medical consultancy services. With an extensive operational network, the company offers over 2,300 tests across various specialties and disciplines.
Suraksha Diagnostic operates a central reference laboratory, 8 satellite laboratories, and 194 customer touchpoints, including 48 diagnostic centers and 146 sample collection centers. The company also provides both online and offline medical consultation services at its 43 diagnostic centers, which house 120 polyclinics with more than 750 doctors.
To support the efficient operation of its diagnostic centers, the company utilizes advanced technology platforms such as its Laboratory Information Management System (LIMS), Radiology Information System (RIS), Picture Archive Communication System (PACS), and Enterprise Resource Planning (ERP) system.
In addition, Suraksha Diagnostic offers vaccination services and customized testing packages for disease prediction and early detection. The company leverages digital pathology and artificial intelligence to enhance blood testing, and all radiology reports are generated through a digital platform, ensuring faster turnaround times across all diagnostic centers.
About the sector and growth potential:
According to the CRISIL Report, the diagnostics services market in India is estimated to at approximately Rs.860 to Rs.870 billion in Fiscal 2024 and is projected to grow at CAGR of around 10% to 12% to reach approximately. Rs.1,275-Rs.1,375 billion by Fiscal 2028. Compared to the overall Indian diagnostics services market, the diagnostics services market in eastern and north-eastern India was estimated at approximately Rs.170-Rs.180 billion in the Fiscal 2024 and is projected to grow at a higher CAGR of around 10.50% to 12.50% to reach approximately Rs.260-Rs.280 billion by Fiscal 2028. The diagnostics services market in India has witnessed a shift from standalone diagnostic centres to diagnostic chains.
Its Operational Network
As of March 31, 2024, its operational network comprises a diagnostic center network of (i) 13 hub centres, which are equipped to conduct all pathology sample collections, basic and advanced radiology tests; and (ii) our ‘spoke’ diagnostic centres which include our 10 medium centers, 23 small centres and 2 centres operated under public private partnership (“PPP”) model, which are equipped to conduct all pathology sample collection and certain basic radiology tests, further supported by 146 sample collection centres (primarily franchised); and a laboratory network of (i) our flagship central reference laboratory; and (ii) 8 satellite laboratories which are co-located with certain hub centres.
For more information, click https://www.surakshanet.com/
Suraksha Diagnostic IPO GMP grey market premium, review, Subscription, allotment, listing estimate
Suraksha Diagnostic IPO Details |
|
| IPO opens on | 29 November 2024 |
| IPO closes on | 3 December 2024 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 19189330 Shares / Rs 846.25 Crore |
| * Fresh Issue | – |
| * Offer for Sale | 19189330 shares/ Rs.846.25 Crore |
| Face Value per share: | Rs. 2 |
| Price Band | Rs. 420-441 |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 34 Shares |
| Listing will at | BSE, NSE |
| Shares offered in Suraksha Diagnostic ? | Shares | Rs. in Crore |
| QIB (50 %) net | 95.94 L | 423.12 |
| NII (15 %) | 28.78 L | 126.94 |
| RII (35 %) | 67.16 L | 296.19 |
| Employees | – | – |
| Total Shares | ||
| Retail portion oversubscribed by | 197537Forms. | |
| How to apply in Suraksha Diagnostic IPO? | Amount Rs. |
|
| Min Retail Appli | 34 | 14994 |
| Max Retail Appli | 442 | 194922 |
| Small HNI (Min) application | 476 | 209916 |
| Small HNI (Max) application | 2244 | 989604 |
| Big HNI Application | 2278 | 1004598 |
What is the timetable of
|
|
| IPO opens on | 29 November 2024 |
| IPO Closes on | 3 December 2024 |
| IPO Allotment on | 4 December 2024 |
| Unblocking of ASBA | 5 December 2024 |
| Credit of Shares | 5 December 2024 |
| Listing on | 6 December 2024 |
| Registered Office of the company | |
| Suraksha Diagnostic Limited Plot No. DG-12/1 Action Area 1D, Premises No. 02-0327 New Town, Rajarhat Kolkata 700 156 Phone: 91 33 66059750 |
|
| Who are the Lead Managers of Suraksha Diagnostic IPO? ICICI Securities Limited Nuvama Wealth Management Ltd SBI Capital Markets ltd |
|
| Registrar to IPO | |
| Kfin Technologies ltd |
Suraksha Diagnostic IPO Financial & Analytical Ratios |
||||
| Year | Total Income | Net Profit | EPS | RoNW |
| Rs. in Cr | Rs.in Cr | Rs. | % | |
| 2021-22 | 225.77 | 20.82 | 3.91 | |
| 2022-23 | 193.69 | 6.07 | 1.22 | |
| 2023-24 | 222.26 | 23.13 | 4.43 | – |
| Book Value of the Share on 31.03.2024 |
Rs. | 33.66 | ||
| BV after the IPO | Rs. | ? | ||
| Offer Price at Cap | Rs. | 441 | ||
| Suraksha Diagnostic IPO Ratio Analysis |
|
| Price /EPS | 99.54 |
| Price/Book Value Ratio | 13.10 |
| Price/BV after IPO | ? |
How Suraksha Diagnostic IPO compares with the Peers?
Peer Comparison.
| Company Name | Total Income Rs. Crore |
PE |
| Suraksha Diagnostics | 218.71 | 99.54 |
| Dr Lal Pathlab | 2226.60 | 68.88 |
| Metropolis Healthcare | 1207.71 | 82.57 |
| Thyrocare | 571.88 | 47.60 |
| Vijaya Diagnostics | 547.80 | 67.65 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Suraksha Diagnostic IPO Review
Will update soon.
Quicklinks
